Value of infliximab (Remicade (R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group

F. Baron, S. Suciu, S. Amadori, P. Muus, H. Zwierzina, C. Denzlinger, M. Delforge, A. Thyss, D Selleslag, K. Indrak, G.J. Ossenkoppele, T.M. de Witte

Research output: Contribution to journalArticleAcademicpeer-review

21 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)529-533
Issue number4
Publication statusPublished - 2012

Cite this